NEW YORK, NY / ACCESSWIRE / December 16, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Domo, Inc. ("Domo" or the "Company") (NASDAQ:DOMO) and certain of its officers, on behalf of shareholders who purchased Domo securities (1) from June 26, 2018 through September 5, 2019, inclusive (the "Class Period"); or (2) pursuant and/or traceable to the Company's registration statement and related prospectus issued in connection with the Company's initial public offering ("IPO" or the "Offering") commenced on or about June 29, 2018. Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/domo.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.

The Complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Domo was experiencing weakness in its enterprise and international businesses; (2) Domo's billings growth had dramatically slowed; (3) all of the foregoing was reasonably likely to have a material negative impact on the Company's financial results; and (4) as a result, Domo's public statements were materially false and misleading at all relevant times.

If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/domo or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Domo you have until December 16, 2019 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 570303

NEW YORK, NY / ACCESSWIRE / December 16, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against X Financial ("X Financial" or the Company") (NYSE:XYF) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired X Financial American Depositary Shares ("ADSs") pursuant and/or traceable to the Company's September 19, 2018 initial public offering (the "IPO"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/xyf.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1933.

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company's total loan facilitation amount was not growing, but rather was contracting; (2) the number of investors actively using X Financial's platform was shrinking; (3) demand from small- and medium-sized enterprises for the Company's Xiaoying Preferred Loans ("preferred loans") was plummeting; (4) the Company's preferred loans had performed so poorly that it had begun drastically scaling back its preferred loans in the first quarter of 2018, several months before the IPO, and was in the process of phasing out such loans completely; (5) demand for the Company's Xiaoying Card Loans was also plummeting; (6) the revenue and loan facilitation growth provided in the Registration Statement leading up to the IPO was achieved by relaxed credit and due diligence standards, under which the Company had underwritten tens of millions of dollars' worth of poor quality loans that suffered from a disproportionately high risk of default as compared to the Company's earlier loan vintages; (7) the Company was suffering from accelerated delinquency rates from poor quality loans that it had underwritten in the first, second, and third quarters of 2018, which had caused the Company's delinquency rate to sharply rise; (8) the Company's product mix had significantly deteriorated; (9) the Company's net revenue was on track to decline by 22% during the third quarter of 2018; and (10) as a result, defendants' statements about X Financial's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/xyf or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in X Financial you have until February 7, 2020 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 570319

NEW YORK, NY / ACCESSWIRE / December 16, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Net 1 UEPS Technologies, Inc. ("UEPS" or the Company") (NASDAQ:UEPS) and certain of its officers, on behalf of shareholders who purchased UEPS securities between September 12, 2018 and November 8, 2018, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/ueps.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company lacked effective internal control over financial reporting; (2) the Company had misclassified its investment in Cell C Proprietary Limited; (3) the Company's financial statements for the fiscal year 2018 were overstating its income; and (4) as a result, UEPS's public statements were materially false and misleading at all relevant times.

If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/ueps or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in UEPS you have until February 3, 2020 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 570318

NEW YORK, NY / ACCESSWIRE / December 16, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Prudential Financial, Inc. (NYSE:PRU)

Class Period: February 15, 2019 – August 2, 2019

Deadline: January 27, 2020
For more info: www.bgandg.com/pru

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company's reserve assumptions failed to account for adversely developing mortality experience in its Individual Life business segment; (2) the Company was not over-reserved, but instead, its reported reserves, particularly for the Individual Life business segment, were insufficient to satisfy its future policy benefits liabilities; (3) the Company had materially understated its liabilities and overstated net income as a result of flawed assumptions in calculating mortality experience; and (4) as a result, Prudential's public statements were materially false and misleading at all relevant times.

Fiat Chrysler Automobiles N.V. (NYSE:FCAU)

Class Period: February 26, 2016 – November 20, 2019

Deadline: January 31, 2020
For more info: www.bgandg.com/fcau

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Fiat employed a bribery scheme to obtain favorable terms in its collective bargaining agreement with International Union, United Automobile, Aerospace and Agricultural Implement Workers of America; (2) high-ranking Fiat official were aware of and authorized the scheme; and (3) due to the foregoing, defendants' statements about Fiat's receivables, business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Merit Medical Systems, Inc. (NASDAQ:MMSI)

Class Period: February 26, 2019 – October 30, 2019

Deadline: February 3, 2020
For more info: www.bgandg.com/mmsi

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the integrations of Cianna and Vascular Insights, including their products, sales people, and R&D facilities, had caused operational disruptions and reduced sales and were months behind schedule; (2) sales of acquired company products had slowed substantially due to pre-acquisition pipeline fill, in particular for Vascular Insights products which, as late as July 2019, had zero orders during fiscal 2019; and (3) in light of the foregoing, the Company's reported financial guidance for fiscal 2019 and 2020 was made without a reasonable basis.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 570317

NEW YORK, NY / ACCESSWIRE / December 16, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Baxter International Inc. (NYSE:BAX)

Class Period: February 21, 2019 – October 23, 2019

Deadline: January 24, 2020
For more info: www.bgandg.com/bax

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) certain intra-Company transactions, undertaken for the purpose of generating foreign exchange gains and losses, used foreign exchange rate conventions that were not in accordance with GAAP and enabled intra-Company transactions to be undertaken after the related exchange rates were already known; (2) Baxter lacked effective internal control over financial reporting; (3) as a result, Baxter's financial statements were misstated and would likely require correction or amendment; (4) due to Baxter's internal investigation, it would not be able to file its quarterly report for the period ending September 30, 2019, with the SEC on a Form 10-Q in a timely manner; and (5) as a result of the foregoing, defendants' statements about Baxter's business and operations lacked a reasonable basis.

HEXO Corp. (NYSE:HEXO)

Class Period: January 25, 2019 – November 15, 2019

Deadline: January 27, 2020
For more info: www.bgandg.com/hexo

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Hexo's reported inventory was misstated as the Company was failing to write down or write off obsolete product that no longer had value; (2) Hexo was engaging in channel-stuffing in order to inflate its revenue figures and meet or exceed revenue guidance provided to investors; (3) Hexo was cultivating cannabis at its facility in Niagara, Ontario that was not appropriately licensed by Health Canada; and (4) as a result, Hexo's public statements were materially false and misleading at all relevant times.

The RealReal, Inc. (NASDAQ:REAL)

Class Period: RealReal securities pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with the Company's June 2019 initial public offering ("IPO" or the "Offering")

Deadline: January 24, 2019
For more info: www.bgandg.com/real

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) that the Company's employees received little training on how to spot fake items; (2) that the Company's strict quotas on its employees exacerbated product authentication issues; (3) that consequently, the potential for counterfeit or mislabeled items to make it through Company's authentication process was higher than disclosed; and (4) that, as a result, defendants' statements about RealReal's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 570316

Not for distribution to United States newswire services or for dissemination in the United States

OTTAWA, ON / ACCESSWIRE / December 16, 2019 / InterRent Real Estate Investment Trust (TSX:IIP.UN) ("InterRent") announced today that its distribution declared for the month of December 2019 is $0.025833 per Trust unit, equal to $0.31 per Trust unit on an annualized basis. Payment will be made on or about January 15, 2020 to unitholders of record on December 31, 2019.

About InterRent

InterRent REIT is a growth-oriented real estate investment trust engaged in increasing Unitholder value and creating a growing and sustainable distribution through the acquisition and ownership of multi-residential properties.

InterRent's strategy is to expand its portfolio primarily within markets that have exhibited stable market vacancies, sufficient suites available to attain the critical mass necessary to implement an efficient portfolio management structure and, offer opportunities for accretive acquisitions.

InterRent's primary objectives are to use the proven industry experience of the Trustees, Management and Operational Team to: (i) to grow both funds from operations per Unit and net asset value per Unit through investments in a diversified portfolio of multi-residential properties; (ii) to provide Unitholders with sustainable and growing cash distributions, payable monthly; and (iii) to maintain a conservative payout ratio and balance sheet.

For further information about InterRent please contact:

Mike McGahan
Chief Executive Officer
Tel: (613) 569-5699 Ext 244
Fax: (613) 569-5698
e-mail: mmcgahan@interrentreit.com

Brad Cutsey, CFA
President
Tel: (613) 569-5699 Ext 226
Fax: (613) 569-5698
e-mail: bcutsey@interrentreit.com

Curt Millar, CPA, CA
Chief Financial Officer
Tel: (613) 569-5699 Ext 233
Fax: (613) 569-5698
e-mail: cmillar@interrentreit.com

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

SOURCE: InterRent Real Estate Investment Trust

ReleaseID: 570356

– Consistent evidence of symptomatic improvement across endpoints and favorable tolerability
– Higher dose demonstrated trend towards significance on primary endpoint
– Both doses statistically superior to vehicle on key secondary endpoints
-Company plans to advance ARQ-151 development in atopic dermatitis, with Phase 2b initiation anticipated in 2H 2020

WESTLAKE VILLAGE, CA / ACCESSWIRE / December 16, 2019 / Arcutis Biotherapeutics, Inc., a privately held late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced top line results for a Phase 2 proof-of-concept study evaluating ARQ-151 as a potential topical treatment for atopic dermatitis (AD). ARQ-151 is a once daily topical cream formulation of roflumilast, a highly potent and selective Phosphodiesterase type 4 inhibitor (PDE4), which the Company is developing for plaque psoriasis and AD.

The ARQ-151-212 study was a Phase 2 multi-center, double blind, vehicle-controlled proof-of-concept study, in which 136 adolescents (ages 12 years and above) and adults with mild to moderate AD involving between 1.5% and 35% body surface area (BSA) were randomized to receive once daily topical applications for 4 weeks of: (1) ARQ-151 0.15% cream, or (2) ARQ-151 0.05% cream, or (3) vehicle. The study assessed the safety, tolerability, pharmacokinetics (PK) and efficacy of the two dose levels of ARQ-151.

On the study's primary endpoint, the mean reduction in the Eczema Area and Severity Index (EASI) Total Score after 4 weeks of once-daily treatment, neither dose reached statistical significance versus vehicle, although ARQ-151 0.15% showed a trend towards significance, with a mean improvement of 6.4 in patients treated with ARQ-151 0.15% compared to 4.8 in patients treated with vehicle (p = 0.097). On the secondary endpoint of mean percent change from baseline on EASI, ARQ-151 0.15% demonstrated a statistically significant improvement versus vehicle (72.3% versus 55.8%, p = 0.049). Efficacy was also observed at both doses as measured by EASI-75 (ARQ-151 0.05%: 59.1% versus vehicle: 31.1%, p = 0.009 and ARQ-151 0.05%: 52.3% versus vehicle: 31.1%, p = 0.045). On the Validated Investigator Global Assessment – Atopic Dermatitis (vIGA-AD), ARQ-151 0.15% also demonstrated a statistically significant improvement versus vehicle in the percentage of patients achieving clear or almost clear (ARQ-151 0.15%: 52.3% versus vehicle: 31.1%, p = 0.040).

In this study, both doses of ARQ-151 were well-tolerated. 95% of subjects on active treatment completed the full study. The incidence of treatment-related Treatment Emergent Adverse Events (TEAEs) and application site reactions were low (< 5%) and similar between active treatment and vehicle. TEAEs were mild to moderate in severity. Among subjects receiving ARQ-151, there was only one Serious Adverse Event (SAE), which was unrelated to treatment, and only one discontinuation due to a TEAE.

Frank Watanabe, Arcutis' Chief Executive Officer, commented: "We are very encouraged by the results from this small, proof-of-concept study. The consistent separation from vehicle on multiple endpoints, and the magnitude of improvement in atopic dermatitis demonstrated in this study further reinforce our belief that ARQ-151 has the potential to be an effective atopic dermatitis therapy. As important, both doses evaluated showed a very favorable tolerability profile, which is particularly important given the majority of atopic dermatitis patients are children. Based on the strength of these results, we plan to pursue further development of ARQ-151 in atopic dermatitis, with a Phase 2b study planned for the second half of 2020."

About ARQ-151

ARQ-151 is a topical cream formulation containing roflumilast, a PDE4 inhibitor, that the Company is developing to treat plaque psoriasis, including intertriginous psoriasis, and atopic dermatitis. PDE4 is an intracellular enzyme that regulates the production of pro-inflammatory and anti-inflammatory cytokines and cell proliferation. Roflumilast is a potent PDE4 inhibitor that was approved by the U.S. Food and Drug Administration (FDA) for systemic treatment to reduce risk of exacerbation of chronic obstructive pulmonary disease (COPD) in 2011, and has shown greater potency based on IC50 values (a non-clinical measure of a drug's potency) than other PDE4 inhibitors.

About Atopic Dermatitis

Atopic dermatitis (AD) is the most common type of eczema, occurring in approximately six percent of the U.S. population. AD is characterized by a defect in the skin barrier, which allows allergens and other irritants to enter the skin, leading to an immune reaction and inflammation. This reaction produces a red, itchy rash, most frequently occurring on the face, arms and legs, and the rash can cover significant areas of the body, in some cases half of the body or more. Disease onset is most common by 5 years of age, and the Company estimates that approximately 60% of patients suffering from AD are pediatric patients. The rash causes significant pruritus (itching), which can lead to skin damage caused by scratching or rubbing. Given that most of the patients are pediatric, the safety and tolerability of AD therapies is paramount.

About Arcutis – Bioscience, applied to the skin.

Arcutis is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. Arcutis exploits recent innovations in inflammation and immunology to develop potential best-in-class therapies against validated biological targets, leveraging our deep development, formulation and commercialization expertise to bring to market novel dermatology treatments, while maximizing our probability of technical success and financial resources. Arcutis is currently developing three novel products (ARQ-151, ARQ-154 and ARQ-252) for multiple indications including psoriasis, atopic dermatitis, seborrheic dermatitis and eczema. For more information, please visit www.arcutis.com or follow Arcutis on LinkedIn.

Contact:

John W. Smither
Chief Financial Officer
jsmither@arcutis.com

Investors and Media:

Derek Cole
720.785.4497
derek.cole@IRadvisory.com

SOURCE: Arcutis Biotherapeutics, Inc.

ReleaseID: 570326

NEW YORK, NY / ACCESSWIRE / December 16, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Energy Transfer LP (NYSE:ET)

Class Period: February 25, 2017 – November 11, 2019

Deadline: January 21, 2020
For more info: www.bgandg.com/et

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Energy Transfer's permits to conduct the Mariner East pipeline project in Pennsylvania were secured via bribery and/or other improper conduct; (2) the foregoing misconduct increased the risk that the Energy Transfer and/or certain of its employees would be subject to government and/or regulatory action; and (3) as a result, Energy Transfer's public statements were materially false and misleading at all relevant times.

Grubhub Inc. (NYSE:GRUB)

Class Period: July 30, 2019 – October 28, 2019

Deadline: January 21, 2020
For more info: www.bgandg.com/grub

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) customer orders were actually declining, despite the massive investments the Company had made to spur demand for and use of its platform; (2) Grubhub's new customer additions were generating significantly lower revenues as compared to historic cohorts because these customers were more prone to using competitor platforms; (3) Grubhub's vaunted business model under which it secured exclusive restaurant partnerships had failed, and Grubhub needed to engage in the same aggressive non-partnered sales tactics embraced by its competitors to generate significant revenue growth; (4) Grubhub was required to spend substantial additional capital in order to grow revenues and retain market share in the face of heightened competitive dynamics and market saturation, eviscerating the Company's profitability; and (5) as a result, Grubhub's public statements were materially false and misleading at all relevant times.

Aurora Cannabis Inc. (NYSE:ACB)

Class Period: September 11, 2019 – November 14, 2019

Deadline: January 21, 2019
For more info: www.bgandg.com/acb

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Aurora Cannabis Inc. ("Aurora" or the "Company")revenue would decline in its first quarter of fiscal 2020 ended September 30, 2019; (2) the Company would halt construction on its Aurora Nordic 2 and Aurora Sun facilities; and (3) due to the foregoing, defendants' statements about Aurora's receivables, business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 570315

NEW YORK, NY / ACCESSWIRE / December 16, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Lipocine Inc. (NASDAQ:LPCN)

Class Period: March 27, 2019 – November 8, 2019

Deadline: January 14, 2020
For more info: www.bgandg.com/lpcn

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the results from Lipocine's clinical studies of TLANDO were insufficient to demonstrate the drug's efficacy; (2) accordingly, Lipocine's third NDA for TLANDO was highly likely to be found deficient by the FDA; and (3) as a result, the Company's public statements were materially false and misleading at all relevant times.

Armstrong Flooring, Inc. (NYSE:AFI)

Class Period: March 6, 2018 – November 4, 2019

Deadline: January 14, 2020
For more info: www.bgandg.com/afi

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company had engaged in channel stuffing to artificially boost sales; (2) the Company's internal control over inventory levels was not effective; and (3) as a result, defendants' statements regarding Armstrong Flooring's business, operations, and prospects, were materially false and misleading. When the true details entered the market, the lawsuit claims that investors suffered damages.

Wanda Sports Group Company Limited (NASDAQ:WSG)

Class Period: WSG securities purchased pursuant and/or traceable to the registration statement and related prospectus (collectively, the "Registration Statement") issued in connection with the Wanda Sports July 2019 initial public stock offering (the "IPO" or the "Offering")

Deadline: January 17, 2020
For more info: www.bgandg.com/wsg

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the lack of major sporting events for its Digital, Production, Sports Solutions ("DPSS") and Spectator Sports segments for its second quarter of 2019, ending before the IPO, would negatively impact revenue for the second quarter of 2019; (2) Wanda Sports had suffered a year-over-year decrease in revenue in its second quarter ended June 30, 2019 and would for its fiscal year 2019, primarily related to lower reimbursement revenues accounted for in its DPSS segment and lack of Spectator Sport segment offsets; and (3) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 570314

NEW YORK, NY / ACCESSWIRE / December 16, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Tandy Leather Factory, Inc. (NASDAQ:TLF)

Class Period: March 7, 2018 – August 15, 2019

Deadline: January 6, 2020
For more info: www.bgandg.com/tlf

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) certain costs of inventory had been improperly valued and expensed; (2) as a result, the Company's financial results for certain periods were misstated; (3) the Company lacked effective internal control over financial reporting; (4) there was a material weakness in the Company's internal control over financial reporting; and (5) as a result, defendants' statements regarding Tandy's business, operations, and prospects, were materially false and misleading. When the true details entered the market, the lawsuit claims that investors suffered damages.

Resideo Technologies, Inc. (NYSE:REZI)

Class Period: October 29, 2018 – October 22, 2019

Deadline: January 7, 2020
For more info: www.bgandg.com/rezi

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the negative operational effects of the Honeywell spin-off were more substantial and persistent than disclosed and had negatively affected the Company's product sales, supply chain, and gross margins, putting Resideo's fiscal 2019 financial forecasts at risk; (2) as a consequence, the Company's financial guidance lacked a reasonable basis and the Company was not on track to make its fiscal 2019 guidance as defendants had claimed; and (3) as a result, Resideo's public statements were materially false and misleading at all relevant times.

Plantronics, Inc. (NYSE:PLT)

Class Period: July 2, 2018 – November 5, 2019

Deadline: January 13, 2020
For more info: www.bgandg.com/plt

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) that the Company had engaged in channel stuffing to artificially boost sales; (2) that the Company's internal control over inventory levels was not effective; (3) that the Company had not adequately monitored inventory levels ahead of multiple product launches, where the new models would displace demand for aging products; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 570313